Publicaciones en las que colabora con Shaji K. Kumar (30)

2024

  1. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee

    The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387

  2. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma

    Blood cancer discovery, Vol. 5, Núm. 3, pp. 146-152

2023

  1. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  2. Disease Monitoring In Multiple Myeloma

    Clinical Lymphoma, Myeloma and Leukemia

2022

  1. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma

    Transplantation and Cellular Therapy, Vol. 28, Núm. 6, pp. 284-293

  2. Correction to: Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis (Advances in Therapy, (2022), 39, 5, (1976-1992), 10.1007/s12325-022-02083-8)

    Advances in Therapy

  3. Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

    Blood cancer discovery, Vol. 3, Núm. 4, pp. 273-284

  4. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

    Blood, Vol. 139, Núm. 6, pp. 835-844

  5. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

    Blood, Vol. 139, Núm. 4, pp. 492-501

  6. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

    Blood, Vol. 140, Núm. 11, pp. 1229-1253

  7. Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis

    Advances in Therapy, Vol. 39, Núm. 5, pp. 1976-1992

2021

  1. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

    Leukemia, Vol. 35, Núm. 1, pp. 18-30

  2. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report

    Blood Cancer Journal, Vol. 11, Núm. 2

  3. Minimal residual disease in Myeloma: Application for clinical care and new drug registration

    Clinical Cancer Research, Vol. 27, Núm. 19, pp. 5195-5212

  4. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

    The Lancet Oncology, Vol. 22, Núm. 3, pp. e105-e118

2020

  1. A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma

    Leukemia, Vol. 34, Núm. 12, pp. 3298-3309

  2. Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set

    Blood, Vol. 136, Núm. 26, pp. 3033-3040

2019

  1. Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies

    European Journal of Haematology, Vol. 102, Núm. 6, pp. 494-503

2018

  1. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

    Blood Cancer Journal, Vol. 8, Núm. 11

2017

  1. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients

    Blood, Vol. 130, Núm. 24, pp. 2610-2618